Bimekizumab-bkzx (Bimzelx, UCB) demonstrated sustained skin clearance and long-term efficacy in moderate-to-severe plaque psoriasis, according to new five-year data presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting.

After five years, 67.7% of patients with moderate-to-severe plaque psoriasis (PsO) on bimekizumab achieved Psoriasis Area and Severity Index (PASI) 100+, and 84.9% achieved PASI90. These results are evident from the first year, where 75.2% achieved PASI100 and 92.8% achieved PASI90.

Data showed 68.7–71.6% of PsO patients at risk of developing psoriatic arthritis (PsA) achieved PASI100, generally consistent with the overall treated group at three years. Similar results were seen in all patients with PsO, including those with PsA at baseline.

Bimekizumab was generally well-tolerated in this patient subgroup, with no unexpected safety findings over five years. In addition, there were no mortalities reported. Safety outcomes were consistent among patients receiving bimekizumab every 4 weeks or every 8 weeks, the study showed.

Saakshi Khattri, MD, a Dermatologist, Rheumatologist, and Internist at the Icahn School of Medicine at Mount Sinai in New York City, chatted with TDD about the new results and how she uses bimekizumab in practice.

TDD: What is the main takeaway message of the new analysis from the second extension of the Phase III BE BRIGHT study?

Saakshi Khattri, MD: “The sustained complete skin clearance seen across five years in the BE BRIGHT study offers key insights into the potential Bimzelx offers in the long-term management of psoriatic disease. For people living with psoriatic disease – particularly those who may have cycled through treatments due to lack of continued response – and those of us who treat these conditions, the five-year data provide meaningful insight into the durable efficacy of this treatment’s dual inhibition. We found that 67.7% of patients with moderate-to-severe plaque psoriasis (PsO) treated with Bimzelx achieved PASI100+ at five years.”

TDD: How do the PASI results stack up to other biologics for PSO?

Dr. Khattri: “These findings, showing sustained complete skin clearance achieved with Bimzelx at five years, demonstrate the robust potential of this treatment to transform patient outcomes across subgroups and add to a growing body of research. As a clinician, long-term data can be critical in informing treatment planning and conversations with my patients, as it can help guide our discussion around treatment expectations. I know many rheumatologists and healthcare professionals (HCPs) following the Bimzelx data are eager to review the forthcoming results from the head-to-head BE BOLD Phase III trial in psoriatic arthritis.”

TDD: With so many options, how do you decide which PsO Treatment is best for which patient?

Dr. Khattri: “When determining a treatment plan, a collaborative decision-making approach between patient and clinician helps ensure that a patient’s preferences, values, and lifestyle are factored into the treatment plan, alongside clinical evidence. The psoriasis treatment landscape has evolved in recent years, so I often encourage people who are unhappy with their current medication or have not seen the same results recently to consider exploring new treatment options. With these exciting new data, in addition to the data supporting the FDA approval of Bimzelx in moderate-to-severe plaque psoriasis, Bimzelx has become a key option when discussing treatment with my patients.” 

TDD: Are there particular patients that you start on bimekizumab?

Dr. Khattri: “When considering starting a patient on any biologic, I begin with a detailed conversation about treatment goals and needs to ensure we are aligned on a treatment that best addresses their treatment needs. For me, Bimzelx stands out because it has shown remarkable results in clinical studies in terms of being able to offer rapid, maintained, and complete skin clearance. These endpoints represent real goals for people living with psoriasis who want to have skin that stays clear long-term. With nearly nine in 10 patients achieving 90% clearer skin at 16 weeks and more than six in 10 reaching complete skin clearance, the rapid and complete clearance offered with Bimzelx makes it a strong option.

Additionally, these latest results showing the five-year sustained efficacy of Bimzelx align well with the treatment goals of those looking for lasting management of their condition.“